Priming with XXXX or @entity3369 prevents @entity1937 -mediated @entity2003 and difficult ventilation.

@entity1 @entity2003 @entity3369 @entity1875 @entity2898 @entity1937
PURPOSE: The aim of this study was to test our hypothesis that priming with @entity2898 would prevent @entity2003 and difficult ventilation due to @entity1937 administration. METHODS: One hundred @entity1 , American Society of Anesthesiologists (ASA) status I or II, were recruited into the study, and randomly allocated to one of four protocols (n = 25 each). @entity1937 was administered at 0.2 microg.kg(-1).min(-1) in group A and at 0.7 microg.kg(-1).min(-1) in groups B, C, and D. Priming with @entity3369 (0.02 mg.kg(-1)) or @entity2898 (0.06 mg.kg(-1)) was performed at the same time as the infusion of @entity1937 in groups C and D, respectively. Anesthesia was induced with 1 mg.kg(-1) @entity1875 2 min after the start of @entity1937 infusion. After the @entity1 had lost consciousness, the anesthesiologist performed mask ventilation, and watched for the presence of @entity2003 . Ventilation and @entity2003 were evaluated using a scoring system. RESULTS: Of the 100 @entity1 , 9 were excluded; the number of @entity1 in group A was 24, while groups B and D had 22 @entity1 each, and group C had 23 @entity1 . A lower dose of @entity1937 (group A) or priming with @entity3369 or @entity2898 (groups C, D) significantly reduced the incidence of some difficulty with ventilation (P = 0.0010, P = 0.0053, and P = 0.021, respectively, vs group B). Of the @entity1 in group B, 10 (45.5%) developed some difficulty with ventilation, and ventilation was impossible in 2 of them. On the other hand, 1 (4.1%) of the @entity1 in group A, 2 (8.7%) in group C, and 3 (13.6%) in group D developed some difficulty with ventilation. CONCLUSION: The present study showed that priming with @entity2898 or @entity3369 reduced the incidence of difficult ventilation by avoiding the @entity2003 caused by @entity1937 .
